JAMA Neurol: tau-PET tracers RO948 F18 have a high degree of identification for Alzheimer's disease

The diagnostic properties of the second generation tau positron emission tomography (PET) tracer are not clearRecently, researchers evaluated the ability of the new tau-PET tracer RO948 F18 (18F) RO948 to identify Alzheimer's disease (AD) and non-AD neurodegenerative diseasesstudy, conducted in Sweden, involved a total of 613 participants, including 257 cognitively normal control groups, 154 patients with mild cognitive impairment, 100 patients with AD dementia and 102 patients with non-AD neurodegenerative disease, compared head-to-head comparisons with patients with primary sexual aphasia (svPPA) with svPPAThe main endpoints of the study were I-II (inner olfactory cortex), III-IV (lower/midaxyl, shuttle, hippocampus and amygdala), I-IV and V-VI (extensive neocorticoid region) region under-the-line trace characteristic curve (AUC)of the 613 participants, the average age of the normal cognitive participants was 65.8 years, 46% were male, the average age of patients with mild cognitive impairment was 70.8 years and 53% were men, the age of aD dementia was 73.5 years, the age of men was 57%, and the average age of non-AD patients was 70.5 years and the male was 40%The retention rate of the AD dementia group was higher than that of all other diagnostic groups(18F) RO948 effectively distinguishes between patients with AD dementia, non-cognitive impairment and non-AD disorders, and is significantly better than MRI and cerebrospinal fluid assays in I-IV use to obtain the highest AUC (AD vs no cognitive impairment, AUC s 0.98; AD vs no AD disorder, AUC-0.97)Typically, tau-PET positives using the use of RO948 are only observed in A beta-positive cases or MAPT R406W mutation carriersThe retention of the RO948 in the patients of svPPA was not obvious, and the head-to-head comparison showed that the temporal lobe intake rate was lower than that of the svPPAstudies have shown that tau-PET tracers RO948 F18 are highly specific to AD tau lesions and have potential diagnostic value in the differential diagnosis of AD